EMERGENT BIOSOLUTIONS INC. Form 8-K (Sept. 30, 2021)

Summary

A Form 8-K current report of Emergent BioSolutions Inc. dated September 30, 2021, signed by Richard S. Lindahl, Executive Vice President, Chief Financial Officer and Treasurer. Under Item 1.01 the company's subsidiary Emergent Product Development Gaithersburg Inc. received Modification No. 11 to the AV7909 development and procurement contract with the Biomedical Advanced Research and Development Authority. Modification No. 11 seeks to procure additional doses of AV7909 (anthrax vaccine adsorbed with adjuvant) for delivery into the Strategic National Stockpile, valued at approximately $399 million, with deliveries over the next 18 months.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 30, 2021

EMERGENT BIOSOLUTIONS INC.

(Exact name of registrant as specified in its charter)

Delaware | 001-33137 | 14-1902018
(State or other jurisdiction | (Commission File Number) | (IRS Employer
of incorporation) | Identification No.)

400 Professional Drive , Suite 400 ,

Gaithersburg , Maryland 20879

(Address of principal executive offices, including zip code)

( 240 ) 631-3200

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, Par Value $0.001 per share | EBS | New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 1.01 Entry Into a Material Definitive Agreement.

On September 30, 2021, Emergent BioSolutions Inc. (including its wholly-owned subsidiaries, “Emergent”), through its wholly-owned subsidiary, Emergent Product Development Gaithersburg Inc., received a contract modification (“Modification No. 11”) to the AV7909 development and procurement contract with the Biomedical Advanced Research and Development Authority (“BARDA”), a component of the Office of the Assistant Secretary for Preparedness and Response, (“ASPR”), an agency of the U.S. Department of Health and Human Services. Modification No. 11 seeks to procure additional doses of AV7909 (anthrax vaccine adsorbed with adjuvant) for delivery into the Strategic National Stockpile, valued at approximately $399 million, with deliveries over the next 18 months.

The preceding description of the modification described herein does not purport to be complete and is qualified in its entirety by reference to the full text of the actual modification. The modification, with relevant redactions to protect confidential and sensitive information, is expected to be filed as an exhibit to Emergent’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2021.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EMERGENT BIOSOLUTIONS INC.
Dated: September 30, 2021 | By: | /s/ RICHARD S. LINDAHL
Name: Richard S. Lindahl Title: Executive Vice President, Chief Financial Officer and Treasurer

File and source

File

SEC_EBS_8-K_filed2021-10-01_0001367644-21-000128.htm

Size

32,522 bytes

SHA-256

c67f2a8bbef7c09d1c6524187cb701143d88fd715e9f985eccda2820d266279f

Our copy

SEC_EBS_8-K_filed2021-10-01_0001367644-21-000128.htm

Original

www.sec.gov